Retatrutide + Cagrilintide
Peptide Stack · Combination ConceptGLP-1/GIP/glucagon receptor agonism + amylin signaling
What Is This Combination?
ERP catalog context: Retatrutide 5 mg + Cagrilintide 5 mg -- total 10 mg
A pairing of Retatrutide's investigational triple-receptor metabolic signaling with Cagrilintide's amylin-receptor satiety pathway -- no exact-combination human trial exists, and CagriSema evidence for a different pairing must not be extrapolated to this one.
The Concept
Cagrilintide adds an amylin/satiety pathway to Retatrutide's multi-receptor metabolic profile. Retatrutide is materially different from semaglutide because it also activates GIP and glucagon receptors, so its combination profile with cagrilintide cannot be assumed to resemble CagriSema's.
Meet the Components
Retatrutide
5 mgGLP-1/GIP/glucagon triple-receptor agonist signaling arm
Retatrutide is studied as a triple agonist at GLP-1, GIP, and glucagon receptors -- materially different from semaglutide, which activates only the GLP-1 receptor. It remains an investigational compound.
See the standalone Retatrutide page for its full evidence summary.
Investigational; independent human evidence
View Retatrutideresearch profile →Cagrilintide
5 mgamylin-receptor satiety signaling arm
Cagrilintide adds an amylin-receptor satiety pathway alongside Retatrutide's multi-receptor metabolic signaling.
See the standalone Cagrilintide page for its full evidence summary.
Human evidence (different combination program)
View Cagrilintideresearch profile →How the Roles Fit Together
What the Combination Is Intended to Address
Evidence-Supported Conceptual Domains
- multi-pathway appetite/satiety biology
- body-weight research
- energy balance
- metabolic signaling
Community-Use Themes
The themes below are editorial summaries of commonly discussed community-use patterns. They are not controlled clinical evidence, systematically sourced community data, or established benefits.
- stronger satiety discussions(editorial-summary)
- "food noise" discussions(editorial-summary)
- appetite suppression when a single agent feels insufficient(editorial-summary)
- plateau-related discussions(editorial-summary)
Concerns & Evidence Gaps
Safety Consideration
No combination pharmacokinetic or safety trial exists for this specific pairing.Safety Consideration
Simultaneous exposure to two appetite-suppressing pathways may intensify gastrointestinal intolerance or reduce food intake beyond what either component produces alone.Safety Consideration
Retatrutide remains an investigational compound with an evolving evidence base.Safety Consideration
Retatrutide's additional glucagon-receptor activity makes CagriSema-based extrapolation incomplete and potentially misleading.Safety Consideration
No evidence-based mass ratio has been established for this combination.Safety Consideration
Simultaneous exposure to two agents makes attribution of any effect, and independent titration of either component, substantially harder.
Why Separate Components May Sometimes Be Preferable
Presented as a scientific/practical tradeoff, not a recommendation.
Favoring Separate Administration
- Independent escalation and observation of each component is scientifically cleaner than changing both variables at the same time.
- Retatrutide's investigational status and evolving evidence base are easier to track when it is not combined with a second, differently-evidenced compound.
- Separate administration allows either component to be held or stopped without discontinuing the other.
- No evidence-based ratio exists to guide a fixed combined formulation.
Favoring the Fixed-Ratio Blend
- A single combined vial is more convenient to source and administer than two separate components on two schedules.
Convenience is not evidence of biological superiority.
Evidence Boundary
The components of this combination have been investigated individually to varying degrees. Evidence for an individual component does not automatically establish the safety, efficacy, compatibility, or synergy of the exact combination. Where direct combination studies exist, MitoCore identifies that explicitly. Where they do not, the page describes the biological rationale for the combination rather than presenting the stack itself as a validated therapeutic intervention.
Exact-combination status: No direct exact-combination trial of Retatrutide plus Cagrilintide has been established in the current MitoCore research record. Cagrilintide-plus-semaglutide (CagriSema) evidence must not be used as proof that this different pairing is safe, effective, additive, or synergistic.
Limitations: Retatrutide's additional GIP- and glucagon-receptor activity, absent from semaglutide, means CagriSema's direct human evidence does not extrapolate to this combination. No combination-specific pharmacokinetic or safety trial exists.
Component evidence: Evidence strength varies by component -- Retatrutide remains investigational; Cagrilintide has its own independent human evidence base, including as part of the different CagriSema program. See each component's own standalone page.
Explore the Components
Each component's full evidence base lives on its own standalone research profile.
Retatrutide
Retatrutide is an investigational GIP, GLP-1, and glucagon receptor agonist in Phase 3 development. Human trials report substantial effects on body weight and glucose control, with additional research in liver fat and obesity-related complications. It remains unapproved, and long-term cardiovascular outcomes, uncommon risks, maintenance after treatment, and real-world product quality remain unresolved.
View research profile →Cagrilintide
Cagrilintide is a long-acting amylin analog studied for weight management, both alone and combined with semaglutide (as CagriSema). It mimics the satiety hormone amylin to reduce food intake, and has shown meaningful weight loss in completed Phase 2 and Phase 3 human trials.
View research profile →Disclaimer
See the anecdotal notice above for community-discussion context.
This page does not establish combination efficacy, safety, or compatibility beyond what is explicitly cited above. Always review each component's own standalone research profile for its full evidence base.